All News
CAR-T Therapy: EULAR 2026 Conference Recap
CAR-T therapy in autoimmune disease is moving fast - but is it ready to move beyond specialized referral centers? This EULAR 2026 recap covers the mechanistic data, relapse biology, and access innovations shaping that answer.
Read Article
Insights into Treating Lupus - A Rheum Survey
RheumNow recently surveyed clinicians to better understand current practice patterns, educational needs, and barriers to the use of new, advanced therapies in systemic lupus erythematosus (SLE). A total of 197 clinicians completed the survey.
Read Article
ICYMI: B Cells at the Brink in Sjögren Disease
A recent issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder.
Read Article
EULAR26: Updates in SLE and APS
EurekAlert!
Severe refractory systemic lupus erythematosus (srSLE) is a clinical state conceptualised as persistent high disease activity despite standard care with glucocorticoids and immunosuppressants.
Read Article
B cell Targeting in SLE
MedPage Today
Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.
Read Article
Learn more about the fundamentals of CAR T-cell therapy and its investigational use in autoimmune disease.
Sponsored by Bristol Myers Squibb. https://t.co/VvTOYY3tvz
#CARTCellTherapy https://t.co/ESW8Z5BZSm
Dr. John Cush RheumNow ( View Tweet)
Systemic sclerosis metanalysis of 31 studies (32,134 pts) shows malignancy risk signif increased (SIR 1.66; CI 1.32 - 2.08). Highest: esophageal, liver, cervical, lung, & Heme (SIR 3.35 - 13.95). 7.4 yr mean from SSc to CA dx. https://t.co/IhxvfkMqkf https://t.co/qvxKgvBzWu
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 31 studies (14,548 pts) looked at infection in idiopathic inflamm myopathy (IIMs). Infection prevalence was 24%, primarily Respiratory tract. PJP, aspergillosis, H zoster most prevalent pathogens. Risk factors: older age, male, DM, HTN,MDA5+ (OR 3.41), rapidly https://t.co/Go51MUOQlG
Dr. John Cush RheumNow ( View Tweet)
DMARD Efficacy in RA-ILD
A network meta-analysis in the Journal of Autoimmunity reviews the pharmacologic options for rheumatoid arthritis–associated interstitial lung disease (RA-ILD). RA-ILD guidelines were recently presented by ERS/EULAR, but these were mainly conditional,
Dr. John Cush RheumNow ( View Tweet)
EULAR26: Vasculitis updates: Glucorticoid use in AAV and GCA
EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids. https://t.co/9HI9SwMSSv
Dr. John Cush RheumNow ( View Tweet)
Insights into Treating Lupus - A Rheum Survey
RheumNow recently surveyed clinicians to better understand current practice patterns, educational needs, and barriers to the use of new, advanced therapies in systemic lupus erythematosus (SLE). A total of 197 clinicians completed https://t.co/HNaUK5Q9uq
Dr. John Cush RheumNow ( View Tweet)
ICYMI: B Cells at the Brink in Sjögren Disease
The current issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder. https://t.co/OBFqHYof5m
Dr. John Cush RheumNow ( View Tweet)
RT @minidey #OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous & MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026
Dr. John Cush RheumNow ( View Tweet)
Obexelimab in IgG4-Related Disease: INDIGO Trial
Dr. Henrique Dalmolin reports on abstract OP018 from EULAR 2026.
https://t.co/Wid9ZzESae https://t.co/Qo4y8ebkOn
Dr. John Cush RheumNow ( View Tweet)
B cell Targeting in SLE
Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.
https://t.co/wGaZPnXfID https://t.co/a0fNvdcrbQ
Dr. John Cush RheumNow ( View Tweet)
RHEUM SURVEY> Do you prefer a lupus drug if it has a lupus nephritis indication (when your treating non-renal SLE)? Answer here >> https://t.co/1KridYM9n8 https://t.co/zIqNB5Mc0O
Dr. John Cush RheumNow ( View Tweet)
Missed a session at EULAR 2026?
No problem.
The RheumNow Faculty Reporter team was on the ground covering the studies, debates, and breakthroughs that are shaping the future of rheumatology. From JAK safety and CAR-T therapies to advances in lupus, psoriatic arthritis, and ILD, https://t.co/YZ7oRNXfqU
Dr. John Cush RheumNow ( View Tweet)
EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases
The 2026 EULAR vaccination recommendations, presented by Victoria Furer, were developed by a multinational 25-member task force that include rheumatologists, an https://t.co/AFnsmEYj41
Dr. John Cush RheumNow ( View Tweet)
Missed a session at EULAR 2026?
No problem.
The RheumNow Faculty Reporter team was on the ground covering the studies, debates, and breakthroughs that are shaping the future of rheumatology. From JAK safety and CAR-T therapies to advances in lupus, psoriatic arthritis, and ILD, https://t.co/cKmhq8mAIf
Dr. John Cush RheumNow ( View Tweet)
The North American Expert Consensus on ASCVD Screening in Lupus Nephritis
Drs. Sheila Reyes and Shivani Garg discuss abstract OP094, presented in London at the EULAR 2026 Congress
https://t.co/Vm2QFlO3fL https://t.co/4Xp9tkubLh
Dr. John Cush RheumNow ( View Tweet)
